Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” Designation

Pulmatrix Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” (QIDP) Designation from the FDA

http://markets.businessinsider.com/news/stocks/Pulmatrix-Antifungal-Drug-Candidate-Receives-a-Second-Qualified-Infectious-Disease-Product-QIDP-Designation-from-the-FDA-1002944255

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate for treating fungal infections in the lungs, Pulmazole (PUR1900), has been designated as a “Qualified Infectious Disease Product” (QIDP) in a second indication by the U.S. Food & Drug Administration.

Under the QIDP program, which is designed to speed the development of novel drugs against important pathogens, Pulmatrix will receive five years of additional market exclusivity for Pulmazole (PUR1900). Pulmatrix had previously received QIDP status as well as orphan drug designation from the FDA for Pulmazole (PUR1900) to treat fungal infections in the airways of patients with cystic fibrosis, a rare genetic disease estimated to affect 75,000-100,000 patients worldwide. This new QIDP status expands the eligible ABPA population to include asthmatic patients; 1.5% of adult asthmatics suffer from ABPA.

In its letter to Pulmatrix, the FDA wrote: “We have reviewed your request and conclude that it meets the criteria for QIDP. Therefore we are designating your Itraconazole Inhalation Powder (PUR1900) product for inhalation use as a QIDP for…treatment of pulmonary Aspergillus infections in patients with allergic bronchopulmonary aspergillosis (ABPA).”

“This second QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to severe asthma patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review and significantly expands the potential population we can treat with our Pulmazole product. This designation provides Pulmazole with 5 years of market exclusivity for treatment of fungal lung infections in these patients with ABPA.”

Currently, many asthma patients experience allergic reactions when their lungs become infected with a fungus called Aspergillus. Doctors now try to treat those infections with oral drugs such as corticosteroids and antifungal agents like itraconazole. Oral antifungals have been shown to provide benefit in treating ABPA in asthma patients but are limited by tolerability, safety, and drug-drug interaction concerns based on the dosing profile. Typically these agents require very high oral doses to get enough of the drug to the lungs through the bloodstream to fight the fungus, leading to the safety and tolerability concerns.

Pulmatrix’s goal is to solve this problem by combining itraconazole with its innovative dry powder iSPERSETM technology. The combination of iSPERSETM and itraconazole makes it possible for patients to inhale the drug into their lungs, to the site of infection, where it’s needed while reducing the amount of drug that gets into the systemic circulation which drive the safety and tolerability concerns.

“By delivering the drug directly to the lungs, we should be able to fight the infection far more effectively than the oral drug can, with far fewer side effects and reduced drug-drug interaction concerns,” explained Pulmatrix’s Chief Scientific Officer, David L. Hava, PhD. “That should bring great benefits to patients.”

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including Pulmazole (PUR1900), an inhaled anti-fungal for patients with severe asthma and cystic fibrosis (CF), and PUR1800, a narrow spectrum kinase inhibitor for patients with COPD. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for COPD. Pulmatrix’s product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

Leave a Reply

Your email address will not be published. Required fields are marked *